Interv Akut Kardiol. 2016;15(1):26-32 | DOI: 10.36290/kar.2016.005

Percutaneous intervention in chronic mitral regurgitation

Vladimír Pořízka, Michael Želízko, Radka Kočková
Klinika kardiologie IKEM, Praha

Significant mitral regurgitation (MR) is a severe disease affecting around 10 % of people above the age of 75 years, and/or with

left ventricular dysfunction, often associated with severe symptoms of heart failure and reduced survival. While surgery remains

the treatment method of choice in low-risk patients with degenerative type of disease, in high-risk patients with functional MR

transcatheter procedure with the MitraClip System is emerging as a safe and effective alternative therapeutic option. Besides this,

several devices, addressing many different anatomical structures of the mitral valve, are under development.

Keywords: mitral regurgitation, mitral valve, MitraClip, transcatheter procedure

Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pořízka V, Želízko M, Kočková R. Percutaneous intervention in chronic mitral regurgitation. Interv Akut Kardiol. 2016;15(1):26-32. doi: 10.36290/kar.2016.005.
Download citation

References

  1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006; 368: 1005-1011. Go to original source... Go to PubMed...
  2. Ling LH, Enriquez-Sarano M. Long-term outcomes of patients with flail mitral valve leaflets. Coron Artery Dis 2000; 11: 3. Go to original source... Go to PubMed...
  3. Gammie JS, Sheng S, Griffith BP, et al. Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg. 2009; 87(5): 1431-1437. Go to original source... Go to PubMed...
  4. Lancellotti P, Magne J. Stress testing for the evaluation of patients with mitral regurgitation. Curr Opin Cardiol. 2012; 27: 492-498. Go to original source... Go to PubMed...
  5. Mirabel M, Iung B, Baron G, Messika-Zeitoun D, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. 2007; 28: 1358-1365. Go to original source... Go to PubMed...
  6. Badhwar V, Peterson ED, Jacobs JP, et al. Longitudinal outcome of isolated mitral repair in older patients: results from 14,604 procedures performed from 1991 to 2007. Ann Thorac Surg. 2012; 94: 1870-1877. Go to original source... Go to PubMed...
  7. Mehta RH, Eagle KA, Coombs LP, et al. Influence of age on outcomes in patients undergoing mitral valve replacement. Ann Thorac Surg. 2002; 74: 1459-1467. Go to original source... Go to PubMed...
  8. Alfieri O, Maisano F, De Bonis M, et al. The double-orifice technique in mitral valve repair: a simple solution for complex problems. J Thorac Cardiovasc Surg. 2001; 122: 674-681. Go to original source... Go to PubMed...
  9. St Goar FG, Fann JI, Komtebedde J, et al. Endovascular edge-to-edge mitral valve repair: short-term results in a porcine model. Circulation 2003; 108: 1990-1993. Go to original source... Go to PubMed...
  10. Condado JA, Acquatella H, Rodriguez L, et al. Percutaneous edge-to-edge mitral valve repair: 2-year follow-up in the first human case. Catheter Cardiovasc Interv 2006; 67: 323-325. Go to original source... Go to PubMed...
  11. Feldman T, Wasserman HS, Herrmann HC, et al. Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial. J Am Coll Cardiol 2005; 46: 2134-2140. Go to original source... Go to PubMed...
  12. Feldman T, Foster E, Glower DD, A, Skipper ER, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011; 364: 1395-1406. Go to original source... Go to PubMed...
  13. Mauri L, Foster E, Glower DD, et al. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol 2013; 62: 317-328. Go to original source... Go to PubMed...
  14. Baldus S, Schillinger W, Franzen O, et al. MitraClip therapy in daily clinical practice: initial results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 2012; 14: 1050-1055. Go to original source... Go to PubMed...
  15. Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol 2013; 62: 1052-1061. Go to original source... Go to PubMed...
  16. Nickenig G, Estevez-Loureiro R, Franzen O, et al. Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry. J Am Coll Cardiol 2014; 64: 875-884. Go to original source... Go to PubMed...
  17. Puls M, Lubos E, Boekstegers P, et al. One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. Eur Heart J. 2015 Nov 27. pii: ehv627. [Epub ahead of print]. Go to original source... Go to PubMed...
  18. Jimmy MacHaalany, MD, a Luc Bilodeau, MD, b Rainer Hoffmann, MD, et al. Treatment of functional mitral valve regurgitation with the permanent percutaneous transvenous mitral annuloplasty system: Results of the multicenter international Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients with Heart Failure trial. Am Heart J. May 2013; 165(5): 761-769. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.